Tallac Therapeutics is founded in 2018, operates from its headquarter in 866 Malcom Rd Suite 100 Burlingame, US. The company operates in the Business Services, Research & Development sector.
Tallac Therapeutics specializes in Immunotherapy development, Toll-like receptor (TLR9) agonist, Antibody conjugate technology, Cancer treatment research, and offers services including Immunotherapy candidates, Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform, and T-CpG for targeted immune activation.
Tallac Therapeutics. During the past 6 months, 1 employees departed.
Total Rounds
US$ 5M
Last Round
US$ 5M
Rounds
1
Investors
Horizon Technology Finance